Overview

Safety and Tolerability of GATE-251 in Normal Human Volunteers

Status:
Completed
Trial end date:
2017-12-21
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of single ascending doses of GATE-251 in normal human volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Ronald M Burch MD PhD